Large Molecule Bioanalysis done differently

To help you achieve more.

BioAgilytix has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve.

Services Delivered Scientist to Scientist

Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.

Solutions Enabled by World-Leading Expertise

Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.

usa europe labs

Advanced facilities to support all phases of large molecule global studies.

    LinkedIn Company Updates

  • Today Agoview on linkedin

    BioAgilytix

    The biosimilars market is exploding, but neither FDA nor EMA have yet specified exactly what the bioanalytical testing requirements should be for determining a biosimilar’s comparability to a reference biologic. See how AAPS’ Biosimilars Action Program Committee (APC) is working to fill this gap: https://lnkd.in/enYpeEN

  • 1 Day Agoview on linkedin

    BioAgilytix

    Have you heard that NIH recently launched the Partnership for Accelerating Cancer Therapies? The collaboration will focus on identifying, developing, and validating biomarkers to advance new immunotherapy treatments for cancer. Learn more here: https://lnkd.in/eTqxsGD

  • 1 Day Agoview on linkedin

    BioAgilytix

    Find our own Dr. Afshin Safavi highlighted in Bioanalysis Zone’s new “Ask the Experts” feature on Biosimilars. Learn how industry leaders are approaching biosimilars development and their evolving role in the industry here: https://lnkd.in/gT4UzYR